Por: Agência Estado
Groups of patients with Hepatitis C will enter this week with a representation in the Federal Public Prosecutor against the Ministry of Health. The aim is to force the MoH to keep providing two types of Interferon Peguilado- the main drug used to treat the disease in the public system.
Currently, Brazilian System of Health (SUS) offers Interferon Alfa 2a (Roche’s product) and Interferon Alfa 2b (Merck Sharp & Dome’s product). In order to lower costs, brazilian MoH intends to buy just from one suplier since the active ingredient is the same.
Patients claims for the need of mantainig both, because there are patients who do not respond to a drug and are cured with the other.
Click here to see the full text in portuguese.